Antonio Jiménez‐Velasco

3.7k total citations
52 papers, 1.9k citations indexed

About

Antonio Jiménez‐Velasco is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Antonio Jiménez‐Velasco has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 18 papers in Molecular Biology and 18 papers in Genetics. Recurrent topics in Antonio Jiménez‐Velasco's work include Chronic Myeloid Leukemia Treatments (25 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Epigenetics and DNA Methylation (11 papers). Antonio Jiménez‐Velasco is often cited by papers focused on Chronic Myeloid Leukemia Treatments (25 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Epigenetics and DNA Methylation (11 papers). Antonio Jiménez‐Velasco collaborates with scholars based in Spain, United States and Germany. Antonio Jiménez‐Velasco's co-authors include José Román‐Gómez, Anabel Heiniger, Felipe Prósper, Xabier Agirre, António Torres, Leire Gárate, Lucía Cordeu, Edurne San José‐Eneriz, Marı́a José Calasanz and Amaia Vilas‐Zornoza and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Antonio Jiménez‐Velasco

52 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Jiménez‐Velasco Spain	25	1.1k	713	573	332	254	52	1.9k
José Román‐Gómez Spain	34	2.1k 1.9×	793 1.1×	979 1.7×	264 0.8×	372 1.5×	48	3.0k
Sébastien Malinge United States	17	631 0.6×	611 0.9×	191 0.3×	308 0.9×	188 0.7×	33	1.4k
Anabel Heiniger Spain	21	1.1k 1.0×	416 0.6×	498 0.9×	142 0.4×	185 0.7×	23	1.5k
Akihide Yoshimi Japan	23	994 0.9×	683 1.0×	244 0.4×	250 0.8×	231 0.9×	64	1.6k
Zhaohui Feng United States	5	1.5k 1.4×	1.1k 1.5×	234 0.4×	185 0.6×	425 1.7×	7	2.0k
Jochen Buechner Norway	14	990 0.9×	301 0.4×	259 0.5×	140 0.4×	316 1.2×	33	1.4k
Uwe Kordes Germany	21	1.1k 0.9×	163 0.2×	322 0.6×	356 1.1×	250 1.0×	58	1.6k
Patricia Fergelot France	23	666 0.6×	444 0.6×	320 0.6×	301 0.9×	249 1.0×	70	1.6k
Meaghan Wall Australia	23	983 0.9×	266 0.4×	166 0.3×	276 0.8×	330 1.3×	57	1.6k
Jalila Chagraoui Canada	24	1.2k 1.1×	593 0.8×	174 0.3×	288 0.9×	241 0.9×	53	1.8k

Countries citing papers authored by Antonio Jiménez‐Velasco

Since Specialization

Citations

This map shows the geographic impact of Antonio Jiménez‐Velasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Jiménez‐Velasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Jiménez‐Velasco more than expected).

Fields of papers citing papers by Antonio Jiménez‐Velasco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Jiménez‐Velasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Jiménez‐Velasco. The network helps show where Antonio Jiménez‐Velasco may publish in the future.

Co-authorship network of co-authors of Antonio Jiménez‐Velasco

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Jiménez‐Velasco. A scholar is included among the top collaborators of Antonio Jiménez‐Velasco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Jiménez‐Velasco. Antonio Jiménez‐Velasco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andrades, Álvaro, María Isabel Rodríguez, Juan Carlos Álvarez-Pérez, et al.. (2020). LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancers. 12(12). 3803–3803. 7 indexed citations

Breccia, Massimo, Michael J. Mauro, Elias Jabbour, et al.. (2020). Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION. Blood. 136(Supplement 1). 31–32. 1 indexed citations

Shah, Neil P., Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, et al.. (2019). Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & lymphoma. 61(3). 650–659. 97 indexed citations

Shah, Neil P., Antonio Jiménez‐Velasco, Sarah M. Larson, et al.. (2018). Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE). Clinical Lymphoma Myeloma & Leukemia. 18. S220–S221. 1 indexed citations

Gallardo, David, Rocío Rodriguez, Ismael Buño, et al.. (2017). Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. Biology of Blood and Marrow Transplantation. 23(12). 2042–2047. 4 indexed citations

García‐Gutiérrez, Valentín, María Teresa Gómez‐Casares, José Manuel Puerta, et al.. (2017). A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS ONE. 12(3). e0173532–e0173532. 4 indexed citations

Hernández‐Boluda, Juan Carlos, Fermín Sánchez‐Guijo, María Teresa Gómez‐Casares, et al.. (2016). Safety and efficacy of ponatinib in real world clinical practice. Results from the Spanish Compassionate Use Program. A GELMC study. RISalud Institutional Health Repository of Andalucía. 1 indexed citations

Luna, Irene, Esperanza Such, José Cervera, et al.. (2012). Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology. 91(12). 1845–1853. 6 indexed citations

Gómez‐Casares, María Teresa, Antonio Jiménez‐Velasco, Miguel Ángel García Bello, et al.. (2012). Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Annals of Hematology. 91(8). 1245–1250. 15 indexed citations

10.

Agirre, Xabier, Amaia Vilas‐Zornoza, Antonio Jiménez‐Velasco, et al.. (2009). Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. Cancer Research. 69(10). 4443–4453. 242 indexed citations

11.

José‐Eneriz, Edurne San, Xabier Agirre, Antonio Jiménez‐Velasco, et al.. (2009). Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. European Journal of Cancer. 45(10). 1877–1889. 69 indexed citations

12.

Agirre, Xabier, Antonio Jiménez‐Velasco, Edurne San José‐Eneriz, et al.. (2008). Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. Molecular Cancer Research. 6(12). 1830–1840. 173 indexed citations

13.

Martı́n, Vanesa, Xabier Agirre, Antonio Jiménez‐Velasco, et al.. (2008). Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia‐positive acute lymphoblastic leukemia. Cancer Science. 99(9). 1865–1868. 28 indexed citations

14.

José‐Eneriz, Edurne San, José Román‐Gómez, Lucía Cordeu, et al.. (2008). BCR‐ABL1‐induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. British Journal of Haematology. 142(4). 571–582. 31 indexed citations

15.

Román‐Gómez, José, Antonio Jiménez‐Velasco, Lucía Cordeu, et al.. (2007). WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. European Journal of Cancer. 43(18). 2736–2746. 65 indexed citations

16.

Román‐Gómez, José, Antonio Jiménez‐Velasco, Xabier Agirre, et al.. (2007). Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leukemia Research. 31(11). 1521–1528. 52 indexed citations

17.

Pérez-García, Arianne, Rafael de la Cámara, José Román‐Gómez, et al.. (2007). CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.. Blood. 110(1). 461–467. 69 indexed citations

18.

José‐Eneriz, Edurne San, Xabier Agirre, José Román‐Gómez, et al.. (2006). Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. British Journal of Haematology. 134(2). 137–144. 25 indexed citations

19.

Agirre, Xabier, José Román‐Gómez, Antonio Jiménez‐Velasco, et al.. (2005). ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene. 25(13). 1862–1870. 56 indexed citations

20.

Jiménez‐Velasco, Antonio, Maite Barrios, José Román‐Gómez, et al.. (2005). Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia. 19(3). 336–343. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact